Oncoinvent ASA
ONCIN
주식 순위
#27156
Oncoinvent ASA, a clinical-stage firm based in Oslo, Norway, is dedicated to... Oncoinvent ASA, a clinical-stage firm based in Oslo, Norway, is dedicated to developing innovative radiopharmaceutical treatments for various cancers. Its primary therapeutic agent is Radspherin, an alpha-emitting radiotherapeutic, which is currently undergoing investigation in two Phase 1/2a and one randomized Phase 2 clinical trials. This promising candidate is designed to target and treat malignancies that have metastasized to body cavities, specifically including the peritoneum.
주가
$7.08
시가총액
$31.73M
변동 (1일)
-0.90%
변동 (1년)
6,325.20%
국가
NO
거래 Oncoinvent ASA (ONCIN)
카테고리
Healthcare
Oncoinvent ASA (ONCIN)의 주가 이력
최고 종가: $9.10 (2026-09-01 기준)
최저 종가: $27.86 (2017-12-01 기준)
최저 종가: $27.86 (2017-12-01 기준)
Oncoinvent ASA의 주가 이력 (2017 ~ 2026)
연간 주가 성과
| 연도 | 성과 |
|---|---|
| 2026 (TTM) | 268.35% |
| 2025 | 32.73% |
| 2024 | -64.40% |
| 2023 | -90.91% |
| 2022 | 4.70% |
| 2021 | -41.35% |
| 2020 | 114.55% |
| 2019 | -57.70% |
| 2018 | 64.64% |
| 2017 | 0.00% |
유사 기업 또는 경쟁사의 주가
| 회사 | 주가 | 변동률 1년% | 국가 |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $763.31 | 8.49% |
CH
|
